From targets to therapy: novel drugs in advanced clinical trialsARMITAGE, James O; SPRIGGS, David R.Seminars in oncology. 2004, Vol 31, Num 6, issn 0093-7754, 38 p., SUP16Serial Issue

The proteasomeDALTON, William S.Seminars in oncology. 2004, Vol 31, Num 6, pp 3-9, issn 0093-7754, 7 p., SUP16Article

Unraveling biologic therapy for Bcl-2-expressing malignanciesCOTTER, Finbarr E.Seminars in oncology. 2004, Vol 31, Num 6, pp 18-21, issn 0093-7754, 4 p., SUP16Article

Clinical update: Novel targets in multiple myelomaANDERSON, Kenneth C.Seminars in oncology. 2004, Vol 31, Num 6, pp 27-32, issn 0093-7754, 6 p., SUP16Article

Presentation and subsequent publication rates of phase I oncology clinical trialsCAMACHO, Luis H; BACIK, Jennifer; CHEUNG, Alexander et al.Cancer. 2005, Vol 104, Num 7, pp 1497-1504, issn 0008-543X, 8 p.Article

Early detection and prognosis of ovarian cancer using serum YKL-40DUPONT, Jakob; TANWAR, Meena K; SPRIGGS, David R et al.Journal of clinical oncology. 2004, Vol 22, Num 16, pp 3330-3339, issn 0732-183X, 10 p.Article

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trialHENSLEY, Martee L; MAKI, Robert; VENKATRAMAN, E et al.Journal of clinical oncology. 2002, Vol 20, Num 12, pp 2824-2831, issn 0732-183XArticle

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancerDIZON, Don S; HENSLEY, Martee L; POYNOR, Elizabeth A et al.Journal of clinical oncology. 2002, Vol 20, Num 5, pp 1238-1247, issn 0732-183XArticle

The Impact of Non-Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I TrialsLASONOS, Alexia; GOUNDER, Mrinal; SPRIGGS, David R et al.Clinical cancer research (Print). 2012, Vol 18, Num 19, pp 5179-5187, issn 1078-0432, 9 p.Article

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsSIMON, George R; ILARIA, Robert L; MILLER, Mary A et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1233-1241, issn 0344-5704, 9 p.Article

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid TumorsTEW, William P; GORDON, Michael; PSYRRI, Amanda et al.Clinical cancer research (Print). 2010, Vol 16, Num 1, pp 358-366, issn 1078-0432, 9 p.Article

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid TumorsLOCKHART, A. Craig; ROTHENBERG, Mace L; GULTEKIN, David H et al.Journal of clinical oncology. 2010, Vol 28, Num 2, pp 207-214, issn 0732-183X, 8 p.Article

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasAGHAJANIAN, Carol; BURRIS, Howard A; O'CONNOR, Owen A et al.Journal of clinical oncology. 2007, Vol 25, Num 9, pp 1082-1088, issn 0732-183X, 7 p.Article

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancerSABBATINI, Paul J; RAGUPATHI, Govind; TEW, William P et al.Clinical cancer research. 2007, Vol 13, Num 14, pp 4170-4177, issn 1078-0432, 8 p.Article

A phase I trial of perillyl alcohol in patients with advanced solid tumorsAZZOLI, Christopher G; MILLER, Vincent A; NG, Kenneth K et al.Cancer chemotherapy and pharmacology. 2003, Vol 51, Num 6, pp 493-498, issn 0344-5704, 6 p.Article

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergyDIZON, Don S; SABBATINI, Paul J; AGHAJANIAN, Carol et al.Gynecologic oncology (Print). 2002, Vol 84, Num 3, pp 378-382, issn 0090-8258Article

Intravenous Aflibercept in Patients With Platinum-Resistant, Advanced Ovarian Cancer: Results of a Randomized, Double-Blind, Phase 2, Parallel-Arm StudyTEW, William P; COLOMBO, Nicoletta; ZHENMING SHUN et al.Cancer. 2014, Vol 120, Num 3, pp 335-343, issn 0008-543X, 9 p.Article

Phase III randomized trial of intravenous cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer : A gynecologic oncology group studySPRIGGS, David R; BRADY, Mark F; VACCARELLO, Luis et al.Journal of clinical oncology. 2007, Vol 25, Num 28, pp 4466-4471, issn 0732-183X, 6 p.Article

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapyLEITAO, Mario M; HUMMER, Amanda; DIZON, Don S et al.Gynecologic oncology (Print). 2003, Vol 91, Num 1, pp 123-129, issn 0090-8258, 7 p.Article

A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignanciesAGHAJANIAN, Carol; SOIGNET, Steven; CANALES, Christina et al.Clinical cancer research. 2002, Vol 8, Num 8, pp 2505-2511, issn 1078-0432Article